Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Method for preparing high-purity human coagulation factor VIII

A human coagulation factor, high-purity technology, applied in the preparation method of peptide, coagulation/fibrinolysis factor, factor VII, etc., can solve the problems of decreased coagulation effect, low specific activity and low specific activity of FVIII, etc., and improve the safety of use. properties, avoid protein damage, and reduce the effect of denaturation and inactivation

Active Publication Date: 2016-02-24
上海洲跃生物科技有限公司
View PDF6 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Foreign recombinant human coagulation factor VIII has entered the Chinese market in 2007, but its high price discourages ordinary patients, and more and more clinical data show that patients who frequently inject recombinant human coagulation factor VIII will produce inhibitors in their bodies , so that the coagulation effect is significantly reduced
[0004] At present, domestic blood product companies supply a very limited number of clinical FVIII products, which is difficult to meet the use requirements of domestic patients with hemophilia A
The reason is mainly that the traditional FVIII production process is unstable, resulting in low product yield. In addition, due to the high content of impurity proteins, the specific activity of FVIII is low, the product is unstable, poor in appearance, and poor in thermal stability, which often leads to product scrapping
[0005] The present invention has developed a new method for separating and purifying FVIII from cryoprecipitate, optimized the parameters of the preparation process, especially adopted a two-step chromatographic purification process, and overcomes the low specific activity (generally lower than 50IU / mg), low yield (generally 100,000 IU / ton of plasma) and poor product appearance (the reconstituted solution of freeze-dried powder has precipitates and obvious opalescence), with high specific activity, stable quality, and qualified rate High advantages, can be produced on a large scale

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for preparing high-purity human coagulation factor VIII
  • Method for preparing high-purity human coagulation factor VIII

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030]1. Cryoprecipitate dissolution: put 1kg cryoprecipitate into 5kg dissolution buffer (0.02MTRIS-HCL, 0.1MNacL, glycine 1.5% (wt%), PH6.50-6.60), add heparin to the dissolution buffer in advance to 2000IU / kg, the temperature is controlled at 15-20°C, and stirred for 3 hours to fully dissolve;

[0031] 2, Al(OH)3 adsorption and pressure filtration: add 0.6kg of Al(OH)3 gel to the above solution, stir thoroughly for 1 hour, then filter with a Supradur50P filter plate produced by Pall in series with a 1.0μm filter element, and collect Clarify the filtrate, and pre-wash the filter plate and filter element with the dissolution buffer described in step 1 before filtering;

[0032] 3. S / D virus inactivation: add Tween80 to 1.0% (wt%) and TNBP (tributyl phosphate) to 0.3% (wt%) to the above filtrate, stir well and heat up to 24-26°C, then keep warm for 6 hours, and then clarified and filtered with a 0.45 μm filter element;

[0033] 4. Anion-exchange column chromatography: The f...

Embodiment 2

[0042] 1. Cryoprecipitate dissolution: 1 kg of cryoprecipitate was dropped into 10 estrogen dissolving buffer (0.02MTRIS-HcL, glycine 0.5%, (wt%), 0.1MNaCL, pH7.30-7.40), and heparin was added to the dissolving buffer in advance. 10000IU / kg, temperature controlled at 25-30°C, stirred for 1.5 hours to fully dissolve;

[0043] 2. Al(OH)3 adsorption and pressure filtration: add 1.65kg of Al(OH)3 gel to the above solution, stir thoroughly for 1.5 hours, then use Pall company's Supradur50P filter plate to filter in series with a 1.0μm filter element, and collect Clarify the filtrate, and pre-wash the filter plate and filter element with the dissolution buffer described in step 2 before filtering;

[0044] 3, S / D virus inactivation: with embodiment one;

[0045] 4. Anion exchange column chromatography: the filtrate after virus inactivation is put on the CaptoDEAE column, and the column is fully equilibrated with the equilibration buffer in advance. l5MCaCL 2 , PH7.30-7.40; after ...

Embodiment 3

[0051] 1. Cryoprecipitate dissolution: put 1kg cryoprecipitate into 7kg dissolution buffer (0.02MTRIS-HCL, 0.15MNaCL, glycine 1.0% (wt%), PH6.90-7.10), add heparin to the dissolution buffer in advance to 6000IU / kg, the temperature is controlled at 20-25°C, and stirred for 2 hours to fully dissolve;

[0052] 2. Al(OH)3 adsorption and pressure filtration: add 0.7kg of Al(OH)3 gel to the above solution, stir thoroughly for 0.5 hours, then use Pall company's Supradur50P filter plate to filter in series with a 1.0μm filter element, and collect Clarify the filtrate, and pre-wash the filter plate and filter element with the dissolution buffer described in step 2 before filtering;

[0053] 3, S / D virus inactivation: with embodiment one;

[0054] 4. Anion-exchange column chromatography: the filtrate after virus inactivation is put on the QSePharose4FF column, and the column is fully equilibrated with the equilibration buffer in advance. 0.01MCacL2, PH6.90-7.10; after loading the col...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a method for preparing a high-purity human coagulation factor VIII from a cryoprecipitate of a human plasma fraction. The method comprises the following steps: (1) cryoprecipitate dissolution; (2) aluminum hydroxide gel adsorption and filter pressing; (3) S / D virus inactivation; (4) anion exchange resin column chromatography; (5) hydrophobic column chromatography; (6) ultrafiltration dialysis and concentration; (7) addition of one or more stabilizers and titer adjustment; (8) nano-membrane virus-removing filtration; (9) sterile filtration and sub-packaging; (10) freeze-drying; (11) dry-heat virus inactivation. The method has the advantages that a human coagulation factor VIII is purified through the two column chromatography steps, so that the prepared high-purity product can reach a specific activity of about 300 IU / mg, considerably higher than about 50 IU / mg in the prior art, and the product appearance and the heat stability are obviously improved; in the preparation process, three virus removing modes are adopted, so that the clinical use safety of the product can be greatly improved.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals and relates to the preparation of a blood product, in particular to a preparation method of high-purity human blood coagulation factor VIII. Background technique [0002] Human coagulation factor VIII (FVIII) is one of the most important coagulation factors in the human body. It is synthesized in the liver. It has 2332 amino acid residues and is composed of two peptide chains. The molecular weight of the heavy chain is 90-200kDa; the molecular weight of the light chain is 80kDa , the two peptide chains are separated by Ca 2+ connect. The half-life in the human body is 8-12 hours, and the content in plasma is only 0.05-0.1 mg / L. [0003] FVIII deficiency can cause coagulation disorders, leading to hemophilia A, which is a genetic disease of coagulation dysfunction caused by mutations in the gene encoding FVIII leading to functional defects of the coagulation factor. It is an X-linked recessive i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/755C07K1/36C07K1/34C07K1/30C07K1/22C07K1/20C07K1/18
CPCC07K14/755
Inventor 李春洲
Owner 上海洲跃生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com